Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL

10.18632/oncotarget.27691

Saved in:

Bibliographic Details
Main Authors:	Chu, Y., Awasthi, A., Lee, S., Edani, D., Yin, C., Hochberg, J., Shah, T., Chung, T.-H., Ayello, J., van de Ven, C., Klein, C., Lee, D., Cairo, M.S.
Other Authors:	CANCER SCIENCE INSTITUTE OF SINGAPORE
Format:	Article
Published:	Impact Journals LLC 2021
Subjects:	Antibody-dependent cellular cytotoxicity Obinutuzumab Primary mediastinal large B-cell lymphoma Rituximab Survival
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/197598
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-197598
record_format	dspace
spelling	sg-nus-scholar.10635-1975982021-08-18T13:20:00Z Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL Chu, Y. Awasthi, A. Lee, S. Edani, D. Yin, C. Hochberg, J. Shah, T. Chung, T.-H. Ayello, J. van de Ven, C. Klein, C. Lee, D. Cairo, M.S. CANCER SCIENCE INSTITUTE OF SINGAPORE Antibody-dependent cellular cytotoxicity Obinutuzumab Primary mediastinal large B-cell lymphoma Rituximab Survival 10.18632/oncotarget.27691 Oncotarget 11 32 3035-3047 2021-08-18T03:34:11Z 2021-08-18T03:34:11Z 2020 Article Chu, Y., Awasthi, A., Lee, S., Edani, D., Yin, C., Hochberg, J., Shah, T., Chung, T.-H., Ayello, J., van de Ven, C., Klein, C., Lee, D., Cairo, M.S. (2020). Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL. Oncotarget 11 (32) : 3035-3047. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.27691 19492553 https://scholarbank.nus.edu.sg/handle/10635/197598 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Impact Journals LLC Scopus OA2020
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	Antibody-dependent cellular cytotoxicity Obinutuzumab Primary mediastinal large B-cell lymphoma Rituximab Survival
spellingShingle	Antibody-dependent cellular cytotoxicity Obinutuzumab Primary mediastinal large B-cell lymphoma Rituximab Survival Chu, Y. Awasthi, A. Lee, S. Edani, D. Yin, C. Hochberg, J. Shah, T. Chung, T.-H. Ayello, J. van de Ven, C. Klein, C. Lee, D. Cairo, M.S. Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL
description	10.18632/oncotarget.27691
author2	CANCER SCIENCE INSTITUTE OF SINGAPORE
author_facet	CANCER SCIENCE INSTITUTE OF SINGAPORE Chu, Y. Awasthi, A. Lee, S. Edani, D. Yin, C. Hochberg, J. Shah, T. Chung, T.-H. Ayello, J. van de Ven, C. Klein, C. Lee, D. Cairo, M.S.
format	Article
author	Chu, Y. Awasthi, A. Lee, S. Edani, D. Yin, C. Hochberg, J. Shah, T. Chung, T.-H. Ayello, J. van de Ven, C. Klein, C. Lee, D. Cairo, M.S.
author_sort	Chu, Y.
title	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL
title_short	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL
title_full	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL
title_fullStr	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL
title_full_unstemmed	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL
title_sort	obinutuzumab (ga101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against cd20+ primary mediastinal b-cell lymphoma (pmbl) in a xenograft nod-scid il2rgnull (nsg) mouse model: a potential targeted agent in the treatment of pmbl
publisher	Impact Journals LLC
publishDate	2021
url	https://scholarbank.nus.edu.sg/handle/10635/197598
_version_	1709685021393027072

Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: A potential targeted agent in the treatment of PMBL

Similar Items